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There is limited, poorly characterized information about adverse events occurring during
maintenance treatment of bipolar disorder. We aimed to determine adverse event rates dur-
ing treatment with lithium, valproate, olanzapine, and quetiapine.
Methods and Findings
We conducted a propensity score adjusted cohort study using nationally representative
United Kingdom electronic health records from January 1, 1995, until December 31, 2013.
We included patients who had a diagnosis of bipolar disorder and were prescribed lithium
(n = 2148), valproate (n = 1670), olanzapine (n = 1477), or quetiapine (n = 1376) as mainte-
nance mood stabilizer treatment. Adverse outcomes were chronic kidney disease, thyroid
disease, hypercalcemia, weight gain, hypertension, type 2 diabetes mellitus, cardiovascular
disease, and hepatotoxicity. The propensity score included important demographic, physi-
cal health, and mental health predictors of drug treatment allocation. The median duration
of drug treatment was 1.48 y (interquartile range 0.64–3.43). Compared to patients pre-
scribed lithium, those taking valproate, olanzapine, and quetiapine had reduced rates of
chronic kidney disease stage 3 or more severe, following adjustment for propensity score,
age, and calendar year, and accounting for clustering by primary care practice (valproate
hazard ratio [HR] 0.56; 95% confidence interval [CI] 0.45–0.69; p < 0.001, olanzapine HR
0.57; 95% CI 0.45–0.71; p < 0.001, quetiapine HR 0.62; 95% CI 0.47–0.80; p < 0.001).
Hypothyroidism was reduced in those taking valproate (HR 0.60; 95% CI 0.40–0.89; p =
0.012) and olanzapine (HR 0.48; 95% CI 0.29–0.77; p = 0.003), compared to those taking
lithium. Rates of new onset hyperthyroidism (valproate HR 0.24; 95% CI 0.09–0.61; p =
0.003, olanzapine HR 0.31; 95% CI 0.13–0.73; p = 0.007) and hypercalcemia (valproate
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HR 0.25; 95% CI 0.10–0.60; p = 0.002, olanzapine HR 0.32; 95% CI 0.14–0.76; p = 0.008,
quetiapine HR 0.23; 95% CI 0.07–0.73; p = 0.013) were also reduced relative to lithium.
However, rates of greater than 15% weight gain on valproate, olanzapine, and quetiapine
were higher (valproate HR 1.62; 95% CI 1.31–2.01; p < 0.001, olanzapine HR 1.84; 95% CI
1.47–2.30; p < 0.001, quetiapine HR 1.67; 95% CI 1.24–2.20; p < 0.001) than in individuals
prescribed lithium, as were rates of hypertension in the olanzapine treated group (HR 1.41,
95% CI 1.06–1.87; p = 0.017). We found no significant difference in rates of chronic kidney
disease stage 4 or more severe, type 2 diabetes mellitus, cardiovascular disease, or hepa-
totoxicity. Despite estimates being robust following sensitivity analyses, limitations include
the potential for residual confounding and ascertainment bias and an inability to examine
dosage effects.
Conclusions
Lithium use is associated with more renal and endocrine adverse events but less weight
gain than commonly used alternative mood stabilizers. Risks need to be offset with the
effectiveness and anti-suicidal benefits of lithium and the potential metabolic side effects of
alternative treatment options.
Author Summary
WhyWas This Study Done?
• Although side effects of medications used for maintenance mood stabilizer treatment in
bipolar disorder have been described, the relative risks of each drug are poorly
understood.
• Randomised, controlled trials are unlikely to be able to give us this information because
they include too few patients, with too short follow-up periods.
• We aimed to examine the rates of a number of adverse effects: renal failure, thyroid dis-
ease, hypercalcemia, hepatotoxicity, weight gain, type 2 diabetes mellitus, hypertension,
and cardiovascular disease in patients taking the most commonly prescribed mood sta-
bilizers in the United Kingdom: lithium, valproate, olanzapine, and quetiapine.
What Did the Researchers Do and Find?
• We conducted a cohort study of individuals with bipolar disorder prescribed lithium
(n = 2148), valproate (n = 1670), olanzapine (n = 1477), or quetiapine (n = 1376),
accounting for key predictors of treatment assignment, such as mental and physical
health history.
• We found that renal failure was more common in patients taking lithium (approxi-
mately 9 in 100 person years at risk) than in those taking the other drugs, but that rates
of severe renal failure were similar in all groups (approximately 1 in 100 person years at
risk).
Adverse Events: Lithium vs. Valproate vs. Olanzapine vs. Quetiapine
PLOSMedicine | DOI:10.1371/journal.pmed.1002058 August 2, 2016 2 / 16
Competing Interests: The authors have declared
that no competing interests exist.
Abbreviations: ALT, alanine transaminase; AST,
aspartate aminotransferase; BMI, body mass index;
BPD, bipolar disorder; CKD, chronic kidney disease;
CVD, cardiovascular disease; CVE, cerebrovascular
event; eGFR, estimated glomerular filtration rate;
ICD-10, International Statistical Classification of
Diseases and Related Health Problems; IHD,
ischemic heart disease; IPW, inverse probability
weights; MI, myocardial infarction; NHS, National
Health Service; NICE, National Institute for Health
and Care Excellence; PS, propensity score; T2DM,
type 2 diabetes mellitus; THIN, The Health
Improvement Network; TSH, thyroid-stimulating
hormone
• The rate of thyroid disease was elevated in people taking lithium, compared to valproate
and olanzapine, but not quetiapine.
• The rate of hypercalcemia was increased with lithium compared to all other drugs.
• The rates of greater than 7% and greater than 15% weight gain were significantly higher
in individuals taking valproate, olanzapine, or quetiapine compared to lithium (for
example, the rate of greater than 15% weight gain in those taking olanzapine was 6 in
100 person years at risk).
• The rate of new onset hypertension was higher in those treated with olanzapine, com-
pared to patients treated with lithium.
• We found no statistically significant differences in rates of type 2 diabetes mellitus, car-
diovascular disease, or hepatotoxicity.
What Do These Findings Mean?
• These findings highlight and quantify the relative risks of commonly used maintenance
mood stabilizer treatments.
• The results for renal failure suggest that despite increasing rates of reduced renal func-
tion in those taking lithium compared to other drugs, severe renal failure is rare. We did
not find differences in severe renal failure rates, which is in keeping with previous
research. However, it is possible that this is due to the small number of people develop-
ing severe renal failure in each group.
• Although we did not find differences in rates of diabetes or cardiovascular disease, this
may be due to relatively short follow-up times and the rarity of these adverse events.
Weight gain is a significant risk factor for these health problems and was dramatically
elevated in alternatives to lithium.
• Assiduous monitoring of patients prescribed lithium should ameliorate some risk associ-
ated with effects on renal physiology and endocrine systems. Calcium monitoring was
rare in this representative cohort of patients with bipolar disorder in UK primary care,
and this needs to be improved in clinical practice.
• The potential adverse effects of each of these drugs need to be balanced with their indi-
vidual therapeutic benefits, and we hope that our findings will permit informed, collabo-
rative discussions with patients.
Introduction
Bipolar disorder (BPD) is a complex, recurrent, severe mental illness that affects over 350 mil-
lion people worldwide [1]. Individuals with BPD will often require long-term drug treatment
with the aim of preventing relapse or reccurrence [2]. Much of the evidence for maintenance
medication comes from relatively short-term randomised controlled trials, which are then
extrapolated to longer-term use [3]. However, this fails to take into account the potential lon-
ger-term adverse effects of the recommended medications. In 2014, the update of the United
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Kingdom National Institute for Health and Care Excellence (NICE) guidelines [3], a meta-
analysis [4], and a network meta-analysis [5] all suggested that lithium should be seen as first-
line monotherapy, whereas previous guidelines from around the world also recommended
valproate, lamotrigine, carbamazepine, olanzapine, quetiapine, aripiprazole, oxcarbazepine,
and risperidone injection [6,7]. Prescribing in the UK has reflected the previous NICE guidance
for first-line treatment [8], with lithium, valproate, olanzapine, and quetiapine being the most
frequently prescribed maintenance treatments [9].
A number of adverse effects of lithium have been identified since its use as a mood stabilizer
became established in the 1970s [10], but it is only recently that they have begun to be charac-
terised and quantified [11–15]. Lithium’s adverse effects include renal, thyroid, and parathy-
roid dysfunction. Lithium is also recognised to cause weight gain, but the risk of weight gain
relative to other potential maintenance therapies has not been widely investigated [11]. Alter-
natives, such as second-generation antipsychotics and valproate, have been found to be obeso-
genic [16], especially olanzapine, which is the most commonly prescribed antipsychotic in
BPD [9]. Weight gain is associated with a number of adverse events, such as hypertension, type
2 diabetes mellitus (T2DM), and cardiovascular disease (CVD) [17]. Valproate, olanzapine,
and quetiapine are metabolized by the liver. Valproate has been found to be associated with a
high risk of asymptomatic elevated transaminases and can cause idiosyncratic hepatic failure
[15,18]. Olanzapine and quetiapine have also been associated with rare cases of hepatotoxicity
[19–21]. Therefore, the balance of risks associated with maintenance mood stabilizer selection
is not straightforward, and we are aware of no studies that make these comparisons across
treatment options.
This study used a large electronic patient record database to compare rates of major recog-
nised adverse outcomes amongst individuals prescribed lithium, valproate, olanzapine, or que-
tiapine for mood stabilization in BPD. The adverse events examined were chronic kidney
disease (CKD), hypothyroidism, hyperthyroidism, hypercalcemia, weight gain, hypertension,
T2DM, CVD, and hepatotoxicity [15,18].
Methods
Study Design
A population-based longitudinal cohort from January 1, 1995, to December 31, 2013.
Setting
The Health Improvement Network (THIN) is a UK primary care database that contains anon-
ymised patient information from routine clinical consultations [16]. The National Health Ser-
vice (NHS) South-East Multicentre Research Ethics Committee approved THIN’s provision of
anonymous patient data to researchers in 2003. Scientific approval for this study was obtained
from the data provider’s Scientific Review Committee in March 2015.
THIN contained records of over 11 million people at the time of cohort extraction [22].
Included patients are broadly representative of the UK population, and physicians contributing
data are representative in terms of consultation and prescribing statistics [23,24]. Approxi-
mately 98% of the UK population is registered with a primary care physician [25]. The inci-
dence rate of BPD in THIN has been shown to be similar to European cohorts [26], and the
validity of severe mental illness diagnoses held in primary care has been established [27]. NICE
guidance recommends that any patient with suspected BPD should be referred to a psychiatrist
for diagnosis and treatment planning [8]. Therefore, individuals in this cohort (psychiatrist-
diagnosed BPD plus appropriate mood stabilizer treatment) are considered to fulfil
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International Statistical Classification of Diseases and Related Health Problems (ICD)-10 crite-
ria for BPD.
In THIN, physicians use Read codes, a hierarchical coding system, to record information
[28]. These codes include diagnoses made in primary and hospital care (which map onto ICD-
10 codes), symptoms, examination findings, information from specialists, and test results [29].
In the UK, primary care physicians are responsible for drug prescriptions issued within the
NHS, so this information is also complete and well recorded [30]. CKD, thyroid disease,
T2DM, hypertension, CVD, and other chronic health condition diagnoses have been validated
in THIN [23].
Participants
Patients with a diagnosis of BPD were included if they had at least one 28-day prescription of
lithium, valproate, olanzapine, or quetiapine after January 1, 1995 or after the date at which the
medical records met quality assurance criteria for data entry (based on computer usage and
mortality recording rates [31,32]). Patients were excluded if they were prescribed another
study drug at the start of follow-up or in the month before this. Diagnosis of BPD could occur
at any time in the patient record. For each outcome requiring hematological or biochemical
confirmation for diagnosis (CKD, thyroid disease, hypercalcemia, hepatotoxicity), patients
were excluded from the primary analysis if they did not receive a specific blood test for the out-
come, to reduce surveillance bias. For the weight gain outcome, patients were excluded if they
did not have a baseline or pre-treatment weight and at least one other weight measurement.
For the outcome of hyperthyroidism, patients taking thyroxine were excluded, as this can result
in thyroid-stimulating hormone (TSH) suppression [33]. Patients were also excluded if they
had the outcome of interest at baseline (as we were interested in incident events). Therefore,
each outcome has a different number of patients included.
Exposure
Date of first prescription was taken as the start of exposure time. The end of the prescription
was calculated from the amount prescribed and dosage instructions coded by the physician.
Patients were considered to have a period of continuous prescribing if another prescription for
the drug was issued within 3 mo of the calculated end date. If this did not occur, the date of
stopping the study drug was the end date of the final prescription. Three mo was added to this
end date to account for late development of the adverse event or delayed recording. Each
patient could only contribute exposure time to one of the study drugs (the first they received)
and did not re-enter the cohort if they restarted the drug after more than 3 mo. Patients could
be prescribed other psychiatric medications but not combinations of the study drugs. If they
commenced another study drug, their outcomes were censored in the analysis (to ensure the
outcome could be assigned to a particular drug).
Main Outcomes
All outcomes were defined by appropriate Read codes and/or lab results. Outcomes of interest
were: CKD stage 3 or above (or an estimated glomerular filtration rate [eGFR] of<60 ml/min/
1.73 m2), CKD stage 4 or above (or an eGFR<30 ml/min/1.73 m2) [34,35] (if eGFR was
unavailable we calculated it from available creatinine blood tests using the CKD-EPI equation
[36]), hypothyroidism (or a TSH of>10 mU/L), hyperthyroidism (or a TSH<0.1 mU/L) [33],
hypercalcemia (adjusted calcium>2.65 mmol/L) [37],>7% and>15% weight gain from base-
line [38], hypertension, T2DM (or HbA1c>48 mmol/mol) [39], CVD (defined as any ische-
mic heart disease [IHD], myocardial infarction [MI] or cerebrovascular event [CVE]), and
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hepatotoxicity (or alanine transaminase [ALT]>200 U/L, or aspartate aminotransferase [AST]
>250 U/L) [40].
Patients were followed up until the earliest of (i) the first record of the adverse event of inter-
est, (ii) the date of stopping the study drug plus 3 mo, (iii) the date of switching to another
study drug, (iv) date of death or date of leaving the physician’s practice, or (v) December 31,
2013.
Propensity Score Estimation Using Observed Pre-treatment Variables
A number of baseline patient characteristics were extracted from THIN. Physical and mental
health conditions were considered present if referenced in patient notes and absent if they were
not. If a patient had multiple entries of the same (or similar) codes, the start date of the condi-
tion was taken as the earliest date of entry.
A propensity score (PS) for each individual was estimated using variables defined a priori,
based on existing research and clinical experience of factors influencing prescribing choice
[3,41,42]. The PS is the conditional probability of receiving one study drug rather than another,
given the variables included in the model [42,43]. Included variables were: sex, age at start of
treatment with the study drug, year of entry to the cohort, ethnicity (grouped as White, Black,
Asian, Mixed, other, with missing values coded as White [44]), IHD diagnosis before baseline,
history of MI, history of CVE, hypertension, CKD at baseline (defined by Read code or blood
test), history of hypo- or hyperthyroidism (defined by Read code or blood test), history of liver
disease or hepatotoxicity (defined by Read code or blood test), T2DM (defined by Read code or
blood test), epilepsy, alcohol use (grouped as none/low, moderate, high/dependent), history of
illicit drug use, smoking status (grouped as never-smoker, ex-smoker, current smoker), body
mass index (BMI) (grouped as healthy weight, overweight [BMI 25 to 30], obese [BMI over
30]), anxiety symptoms or diagnosis before baseline, depressive symptoms or diagnosis, sleep
disturbance before baseline, treatment with one of the study drugs at or before baseline, and
clustering by practice in which the treating physician was working. The PS was checked by
comparison of covariate balance across treatments, within strata. The variables in the PS
excluded the outcome variable for that particular analysis. Although PS estimation cannot
remove all bias, it has been postulated to also reduce confounding from unmeasured covariates,
because of their association with measured variables [45–47]. In this way, use of a PS aims to
replicate a randomized experiment as closely as possible by obtaining treatment groups with
similar covariate distributions [48].
Statistical Analysis
Cox regression analyses were conducted, comparing the rates of adverse events in the four
treatment groups. The proportional hazards model was tested formally with analysis of
Schoenfeld residuals [49]. The PS was calculated using multinomial logistic regression, using
drug treatment as the dependent variable and the covariates described as independent vari-
ables. The PS was then used as a linear term in a Cox regression analysis that also included age,
calendar year, and clustering by practice [50]. In all cases, this model was shown to be superior
to stratifying on PS using Akaike information criterion and Bayesian information criterion
[51], and was a more efficient use of data than PS matching (because no patients were
excluded). To account for the competing risk of each outcome with death, we plotted graphs of
cumulative incidence function, adjusted for PS and age, following competing-risks regression
[52,53]. We conducted sensitivity analyses in which individuals who did not receive blood tests
or weight measurements were not dropped from the cohort, and in which individuals were
assigned inverse probability weights (IPW) based on how likely they were to have blood test or
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weight records [54]. We used multiple demographic and clinical variables to predict missing-
ness for the IPWmodel. All analyses were completed using Stata 14 [55].
Results
For each outcome, 6,671 individuals with BPD diagnosis were potentially included in the anal-
ysis, 2,148 prescribed lithium, 1,670 prescribed valproate, 1,477 prescribed olanzapine, and
1,376 prescribed quetiapine (see S1 Text). The median duration of drug treatment was 1.48 y
(interquartile range 0.64–3.43). The characteristics of the potentially included cohort are
shown in Table 1. The number of individuals included for each outcome by treatment group is
shown in S1 Table.
In unadjusted analysis and after adjustment for PS, age, calendar year, and clustering by
practice in which the primary care physician worked, rates of CKD stage 3 or above in individ-
uals prescribed valproate (HR 0.56; 95% CI 0.45–0.69; p< 0.001), olanzapine (HR 0.57; 95%
CI 0.45–0.71; p< 0.001), or quetiapine (HR 0.62; 95% CI 0.47–0.80; p< 0.001) were reduced
compared to lithium (Table 2, Fig 1).
Compared to lithium, rates of hypothyroidism were reduced in those prescribed valproate
(HR 0.60; 95% CI 0.40–0.89; p = 0.012) or olanzapine (HR 0.48; 95% CI 0.29–0.77; p = 0.003),
but not quetiapine (HR 0.63; 95% CI 0.38–1.05; p = 0.074) after adjustment. Rates of hyperthy-
roidism were lower in those prescribed valproate (HR 0.24; 95% CI 0.09–0.61; 0.003) and
Table 1. Patient characteristics.
lithium valproate olanzapine quetiapine
Total, n 2,148 1,670 1,477 1,376
Female, n (%) 1,287 (59.92) 911 (54.55) 791 (53.55) 959 (69.69)
Age, median (IQR), years 46.28 (35.70–60.67) 42.31 (31.95–54.80) 41.01 (32.03–53.08) 38.08 (29.30–48.71)
Non-white ethnic background, n (%) 55 (2.56) 85 (5.09) 78 (5.28) 43 (3.13)
Duration of drug exposure, median (IQR), years 2.03 (0.77–4.86) 1.48 (0.65–3.35) 1.28 (0.59–3.29) 1.06 (0.56–2.26)
Primary care contacts per year, median (IQR) 11.14 (6.54–18.02) 12.51 (7.36–19.96) 11.94 (7.08–19.55) 14.61 (9.21–22.55)
Health at baseline, n (%)
CVD history 124 (5.77) 121 (7.25) 68 (4.60) 53 (3.85)
CKD3 (or eGFR <60 ml/min/1.73m2) 52 (2.42) 40 (2.40) 27 (1.83) 32 (2.33)
Hypothyroidism (or TSH >10 mU/L) 183 (8.52) 105 (6.29) 60 (4.06) 61 (4.43)
Hyperthyroidism (or TSH <0.1 mU/L) 16 (0.74) 8 (0.48) 9 (0.61) 9 (0.65)
T2DM (or HbA1c >48 mmol/mol) 108 (5.03) 140 (8.38) 45 (3.05) 86 (6.25)
Hepatic impairment (or ALT >200 U/L or AST >250 U/L 34 (1.58) 41 (2.45) 37 (2.51) 19 (1.38)
Obesity (BMI >30) 896 (41.71) 716 (42.87) 509 (34.36) 609 (44.26)
Hypercalcemia (adjusted calcium >2.65 mmol/L) 10 (0.47) 4 (0.24) 2 (0.14) 3 (0.22)
Hypertension 184 (8.57) 173 (10.36) 103 (6.97) 130 (9.45)
Epilepsy 43 (2.00) 132 (7.90) 50 (3.39) 49 (3.56)
Previous anxiety problems 144 (6.70) 150 (8.98) 137 (9.28) 201 (14.61)
Moderate/heavy alcohol use 1,189 (55.35) 899 (53.83) 791 (53.55) 708 (51.45)
Current smoker 711 (33.10) 652 (39.04) 632 (42.79) 567 (41.21)
Bipolar disorder characteristics at baseline, n (%)
Previous depressive episode 1,238 (57.64) 990 (59.28) 915 (61.95) 1,015 (73.76)
Previous record of taking study drug 1,731 (80.59) 1,157 (69.28) 886 (59.99) 847 (61.56)
CVD, cardiovascular disease; CKD, chronic kidney disease; eGFR, estimated glomerular ﬁltration rate; TSH, thyroid stimulating hormone; T2DM, type 2
diabetes mellitus; ALT, alanine transaminase; AST, aspartate aminotransferase; BMI, body mass index
doi:10.1371/journal.pmed.1002058.t001
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Table 2. Adverse effects duringmaintenance treatment.
Lithium Valproate Olanzapine Quetiapine
CKD stage 3 (n = 4,560)
Events, n 489 130 121 71
PYAR (100s) 51.97 29.85 25.64 16.89
Rate, per 100 PYAR (95%CI) 9.41 (8.61–10.28) 4.35 (3.67–5.17) 4.72 (3.95–5.64) 4.20 (3.33–5.31)
Unadjusted HR (95%CI) 1 (reference) 0.46 (0.38–0.55) 0.50 (0.41–0.61) 0.43 (0.33–0.55)
PS Adjusted HR (95%CI) 1 (reference) 0.56 (0.45–0.69) 0.57 (0.45–0.71) 0.62 (0.47–0.80)
p-value <0.001 <0.001 <0.001
CKD stage 4 (n = 4,817)
Events, n 91 34 20 12
PYAR (100s) 63.48 32.75 27.77 18.35
Rate, per 100 PYAR (95%CI) 1.43 (1.17–1.76) 1.04 (0.74–1.45) 0.72 (0.46–1.12) 0.65 (0.37–1.15)
Unadjusted HR (95%CI) 1 (reference) 0.75 (0.51–1.13) 0.52 (0.32–0.85) 0.47 (0.25–0.87)
PS Adjusted HR (95%CI) 1 (reference) 0.94 (0.59–1.50) 0.65 (0.37–1.12) 0.67 (0.33–1.37)
p-value 0.806 0.127 0.273
Hypothyroidism (n = 4,093)
Events, n 183 61 41 33
PYAR (100s) 59.23 27.78 23.79 15.59
Rate, per 100 PYAR (95%CI) 3.09 (2.67–3.57) 2.20 (1.71–2.82) 1.72 (1.27–2.34) 2.12 (1.50–2.98)
Unadjusted HR (95%CI) 1 (reference) 0.69 (0.51–0.94) 0.54 (0.38–0.77) 0.62 (0.42–0.90)
PS Adjusted HR (95%CI) 1 (reference) 0.60 (0.40–0.89) 0.48 (0.29–0.77) 0.63 (0.38–1.05)
p-value 0.012 0.003 0.074
Hyperthyroidism (n = 3,704)
Events, n 41 5 6 6
PYAR (100s) 52.49 25.81 22.62 14.65
Rate, per 100 PYAR (95%CI) 0.78 (0.58–1.06) 0.19 (0.08–0.47) 0.27 (0.12–0.59) 0.41 (0.18–0.91)
Unadjusted HR (95%CI) 1 (reference) 0.24 (0.09–0.61) 0.33 (0.14–0.78) 0.48 (0.20–1.17)
PS Adjusted HR (95%CI) 1 (reference) 0.24 (0.09–0.61) 0.31 (0.13–0.73) 0.45 (0.18–1.18)
p-value 0.003 0.007 0.096
Hypercalcemia (n = 2,094)
Events, n 55 6 6 3
PYAR (100s) 36.29 17.1 13.44 8.99
Rate, per 100 PYAR (95%CI) 1.52 (1.16–1.97) 0.35 (0.16–0.78) 0.45 (0.20–0.99) 0.33 (0.11–1.03)
Unadjusted HR (95%CI) 1 (reference) 0.24 (0.10–0.56) 0.31 (0.14–0.68) 0.24 (0.07–0.76)
PS Adjusted HR (95%CI) 1 (reference) 0.25 (0.10–0.60) 0.32 (0.14–0.76) 0.23 (0.07–0.73)
p-value 0.002 0.008 0.013
T2DM (n = 6,292)
Events, n 150 86 88 51
PYAR (100s) 69.11 36.52 34.01 21.28
Rate, per 100 PYAR (95%CI) 2.17 (1.85–2.55) 2.35 (1.91–2.91) 2.59 (2.10–3.19) 2.40 (1.82–3.15)
Unadjusted HR (95%CI) 1 (reference) 1.21 (0.94–1.55) 1.31 (0.99–1.74) 1.32 (0.95–1.82)
PS Adjusted HR (95%CI) 1 (reference) 1.08 (0.83–1.42) 1.20 (0.89–1.61) 0.94 (0.65–1.35)
p-value 0.586 0.230 0.752
CVD (n = 6,305)
Events, n 94 32 26 21
PYAR (100s) 69.49 37.56 33.41 22.17
Rate, per 100 PYAR (95%CI) 1.35 (1.11–1.66) 0.85 (0.60–1.20) 0.78 (0.53–1.14) 0.95 (0.62–1.45)
Unadjusted HR (95%CI) 1 (reference) 0.67 (0.44–1.04) 0.61 (0.38–0.98) 0.79 (0.47–1.35)
(Continued)
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olanzapine (HR 0.31; 95% CI 0.13–0.73; 0.007), but not quetiapine (HR 0.45; 95% CI 0.18–
1.18; 0.096), compared to lithium. Hypercalcemia was less common in those prescribed valpro-
ate (HR 0.25; 95% CI 0.10–0.60; p = 0.002), olanzapine (HR 0.32; 95% CI 0.14–0.76; p = 0.008),
or quetiapine (HR 0.23; 95% CI 0.07–0.73; p = 0.013) compared to lithium (Table 2, Fig 2).
After adjustment, rates of weight gain were higher with valproate, olanzapine, and quetiapine
than lithium (>15% weight gain: valproate HR 1.62; 95% CI 1.31–2.01; p< 0.001; olanzapine
HR 1.84; 95% CI 1.47–2.30; p< 0.001; quetiapine HR 1.67; 95% CI 1.24–2.20; p< 0.001). Rates
of hypertension were higher with olanzapine (HR 1.41; 95% CI 1.06–1.87; p = 0.017) than lithium
(Table 2, Fig 3). We found no significant difference in rates of CKD stage 4 or above, T2DM, car-
diovascular disease, or hepatotoxicity between groups (Table 2). The median number of eGFR/
creatinine and TSH blood tests per year in treatment was higher in those taking lithium than
the other drugs (see S2 Table). Weight measurement and blood tests for adjusted calcium and
Table 2. (Continued)
Lithium Valproate Olanzapine Quetiapine
PS Adjusted HR (95%CI) 1 (reference) 0.91 (0.59–1.41) 0.85 (0.53–1.36) 1.11 (0.63–1.96)
p-value 0.684 0.509 0.732
>7% weight gain (n = 4,458)
Events, n 467 410 396 299
PYAR (100s) 63.20 33.28 30.56 19.05
Rate, per 100 PYAR (95%CI) 7.39 (6.75–8.09) 12.32 (11.18–13.57) 12.96 (11.74–14.30) 15.70 (14.02–17.58)
Unadjusted HR (95%CI) 1 (reference) 1.90 (1.64–2.20) 1.99 (1.72–2.30) 2.72 (2.33–3.16)
PS Adjusted HR (95%CI) 1 (reference) 1.37 (1.17–1.61) 1.43 (1.23–1.67) 1.37 (1.16–1.62)
p-value <0.001 <0.001 <0.001
>15% weight gain (n = 4,458)
Events, n 179 182 189 130
PYAR (100s) 63.92 34.27 31.24 19.30
Rate, per 100 PYAR (95%CI) 2.80 (2.42–3.24) 5.31 (4.59–6.14) 6.05 (5.25–6.98) 6.74 (5.67–8.00)
Unadjusted HR (95%CI) 1 (reference) 2.29 (1.87–2.82) 2.57 (2.06–3.22) 3.41 (2.61–4.44)
PS Adjusted HR (95%CI) 1 (reference) 1.62 (1.31–2.01) 1.84 (1.47–2.30) 1.67 (1.24–2.20)
p-value <0.001 <0.001 <0.001
Hypertension (n = 6,081)
Events, n 174 85 89 33
PYAR (100s) 64.25 35.66 32.30 20.65
Rate, per 100 PYAR (95%CI) 2.71 (2.33–3.14) 2.38 (1.93–2.95) 2.76 (2.24–3.39) 1.60 (1.14–2.24)
Unadjusted HR (95%CI) 1 (reference) 0.98 (0.75–1.26) 1.11 (0.84–1.46) 0.75 (0.50–1.12)
PS Adjusted HR (95%CI) 1 (reference) 1.19 (0.90–1.58) 1.41 (1.06–1.87) 0.89 (0.59–1.34)
p-value 0.274 0.017 0.590
Hepatotoxicity (n = 3,352)
Events, n 20 10 14 13
PYAR (100s) 50.13 25.95 20.39 12.53
Rate, per 100 PYAR (95%CI) 0.40 (0.26–0.62) 0.39 (0.21–0.72) 0.69 (0.41–1.16) 1.04 (0.60–1.79)
Unadjusted HR (95%CI) 1 (reference) 0.96 (0.45–2.07) 1.71 (0.86–3.40) 2.59 (1.26–5.32)
PS Adjusted HR (95%CI) 1 (reference) 0.65 (0.30–1.39) 1.23 (0.63–2.42) 1.21 (0.54–2.74)
p-value 0.274 0.558 0.658
CKD, chronic kidney disease; T2DM, type 2 diabetes mellitus; CVD, cardiovascular disease; PYAR, person years at risk; HR, hazard ratio; PS, propensity
score. Unadjusted hazard ratio accounts for clustering by primary care practice, adjusted hazard ratio is adjusted for propensity score age group and
calendar period time varying variables and clustering by primary care practice. P-values for PS adjusted HR.
doi:10.1371/journal.pmed.1002058.t002
Adverse Events: Lithium vs. Valproate vs. Olanzapine vs. Quetiapine
PLOSMedicine | DOI:10.1371/journal.pmed.1002058 August 2, 2016 9 / 16
ALT/AST were less frequent in patients prescribed lithium (see S2 Table). For outcomes in
which patients had been excluded because of missing tests (CKD, hypo- and hyperthyroidism,
hypercalcemia, weight gain, and hepatotoxicity), sensitivity analyses including all patients
resulted in reduced incident rate estimates compared to the primary analyses, but had little effect
on HRs (see S3 Table). Sensitivity analyses using IPW suggest results from the primary analyses
are robust (see S3 Table). From Schoenfeld residuals, there was no evidence against the assump-
tion of proportional hazards for any outcome.
Discussion
In a large dataset of nearly 7,000 individuals treated for BPD with lithium, valproate, olanza-
pine, or quetiapine, with follow-up times of up to 17 y, we found differential rates of a number
of adverse events. Those prescribed lithium were more likely to have a decline in renal function
and develop hypo- or hyperthyroidism and hypercalcemia. However, they were less likely to
gain significant weight. Individuals prescribed olanzapine had the highest rate of weight gain
and new onset hypertension. We did not find any statistically significant differences in the rate
of new T2DM, cardiovascular disease, or hepatotoxicity across drug treatment groups.
Severe CKD (stage 4 or above) was uncommon in the cohort (approximately 1 in 100 per-
son years at risk), and we did not find differences by drug treatment, but less severe CKD
Fig 1. Cumulative incidence estimates of adverse renal and hepatic event rates. From PS and age-adjusted competing-risks regression. Note
differences in scale of y-axis for each plot.
doi:10.1371/journal.pmed.1002058.g001
Fig 2. Cumulative incidence estimates of adverse endocrine event rates. From PS and age adjusted competing-risks regression. Note differences in
scale of y-axis for each plot.
doi:10.1371/journal.pmed.1002058.g002
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(stage 3 or above) occurred most frequently in patients prescribed lithium. Whilst many of
these patients (i.e., those with CKD stage 3) would not progress to a clinically relevant decline
in renal function, a number of them would be at increased risk of doing so. It remains unclear
if this result is due to (1) lack of power to determine a true difference in rates of severe CKD,
(2) surveillance bias due to increased monitoring of renal function in those taking lithium,
which would lead to apparent increased rates of asymptomatic CKD stage 3, or (3) lithium
treatment truly increasing the risk of reduced renal function without increasing severe CKD
risk. Previous studies have found similar results and have not been able to account for this
potential bias [12–14,56]. Clos et al. found no decline in eGFR in individuals taking lithium,
using a similar active comparator design, but were also limited by potential ascertainment bias
[57].
Rates of both hypothyroidism and hyperthyroidism were increased in individuals pre-
scribed lithium compared to valproate and olanzapine (but not quetiapine). Increased hypo-
thyroidism has been shown previously [11,58], but literature on the association between
lithium and hyperthyroidism is inconsistent [13], and lithium-induced hyperthyroidism is
considered rare [59]. Monitoring thyroid dysfunction in BPD is vital because of evidence that
abnormalities are associated with longer time to remission and more symptoms during the
maintenance period [60]. It is possible that thyroid function normalises on cessation of lithium,
but only one study has investigated this [61]. Hypercalcemia is also recognised to be associated
with lithium prescribing [11,13,62,63]. Calcium monitoring in patients prescribed lithium was
rare in our representative sample of primary care (37% had one or more calcium blood test
result), despite it being recommended in the 2006 NICE guidance [8].
The rate of individuals gaining more than 7%, and more than 15% of their baseline weight,
was greater in those prescribed olanzapine, quetiapine, or valproate than those prescribed
Fig 3. Cumulative incidence estimates of adversemetabolic event rates. From PS and age adjusted
competing-risks regression. Note differences in scale of y-axis for each plot.
doi:10.1371/journal.pmed.1002058.g003
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lithium. This degree of weight gain represents a significant risk factor for a number of adverse
physical health outcomes, including CVD and T2DM [38]. We may not have captured
increased rates of CVD or T2DM because of the relatively brief median follow-up time, in rela-
tion to the time taken to develop these diseases. Olanzapine had the highest adjusted rate of
greater than 15% weight gain compared to lithium, and the highest rate of new onset hyperten-
sion. This has been shown previously in comparisons of antipsychotic drugs [64] and in trials
of olanzapine versus lithium or valproate [65].
Hepatotoxicity was rare in the cohort and, before PS adjustment rates, appeared to be ele-
vated in the quetiapine group, compared to lithium. This association has been identified previ-
ously [20]. After adjustment, there was no evidence of between-group differences.
Strengths and Limitations
The major strength of this study, beyond size and length of follow-up, is the direct comparison
between BPD maintenance mood stabilizer treatment options for a number of adverse effects.
The use of electronic health records also means it is possible to adjust for a number of demo-
graphic and physical health characteristics that may have influenced the clinician’s decision to
treat with a particular medication or potentially confound the relationship between treatment
and adverse outcome. Despite including numerous variables in the PS, it is possible that resid-
ual confounding remained, especially as those prescribed lithium were older and were more
likely to have taken the drug previously, perhaps reflecting a more chronic illness course. It
may be that important patient or clinician features were not captured by the score, and despite
the balance of observed covariates, we cannot confirm balance of unobserved covariates
[66,67]. We were also unable to consider dosage differences across the different treatment
groups in this analysis. Periods of lithium toxicity may be particularly important with regards
to developing renal failure, and we were unable to capture this information from the available
data. Missing data can be a problem in studies utilising electronic patient records, especially as
there may be a clinical reason why information is missing. Because of the way outcomes were
defined, T2DM, cardiovascular disease, and diagnoses of hypertension had no missing data,
and no covariates in the PS had missing values.
Patients prescribed lithium had no more physician contacts than those taking other mood
stabilizer medication. In individuals that ever received tests during treatment exposure, testing
frequency was similar in all study drugs for adjusted calcium, liver function, and weight (see S2
Table). Frequency of testing renal and thyroid function was higher in those taking lithium,
which reflects the guidance for monitoring [8]. Patients prescribed lithium were also more
likely to have at least one renal function, thyroid function, calcium, or liver function test com-
pared to patients taking other drugs. This is likely to be due to both drug-related indications
for monitoring and the longer drug exposure seen in those taking lithium. IPW sensitivity anal-
ysis to account for this difference did not alter our conclusions (see S3 Table). In the primary
analysis, the likely effect of this differential missingness would be to reduce the hazard ratios
for lithium compared to the other drugs, relative to their true values, as blood tests in the non-
lithium group are more likely to be related to clinical symptoms than monitoring guidance (for
instance, this is likely to represent an underestimation of the true hypercalcemia hazard ratio
for lithium versus other drugs). The median number of weight measurements was similar in
each group, suggesting detection of weight gain was not related to differential monitoring. The
sensitivity analyses including individuals irrespective of blood tests produced similar adjusted
hazard ratios as the primary analyses for each outcome, but often with reduced incidence of
the outcome in each treatment group (see S3 Table). These analyses may more accurately
reflect testing occurring because of clinical indication.
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Conclusions
Lithium remains an important treatment option for individuals with BPD. However, there is
clear evidence that its use is associated with a number of adverse events. These risks need to be
offset with the potentially superior effectiveness and anti-suicidal benefits of the drug com-
pared to other treatment options [5,68]. It is also true that other recommended maintenance
treatments can have serious side effects, often related to weight gain, and are not suitable for
use in certain patient groups (such as the contraindication of valproate in women of childbear-
ing potential [3]).
Assiduous monitoring of patients prescribed lithium should ameliorate some risk associated
with effects on renal physiology and endocrine systems. Given the need to balance an array of
risks and benefits, an individualised and collaborative approach to treatment choice is likely to
be most appropriate. To achieve this, further research identifying patient characteristics that
are risk factors for specific side effects and an understanding of the risks and benefits of stop-
ping treatment in those who experience adverse effects is necessary.
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